Trial Profile

An Open Label Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Maximum Tolerated Dose and Biomarker Response After Intravenous Administration of Weekly BAY80 6946 to Patients With Advanced Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Copanlisib (Primary)
Indications Solid tumours
Focus Adverse reactions; Biomarker; First in man; Pharmacodynamics; Pharmacokinetics
Sponsors Bayer

01 Oct 2016 Status changed from active, no longer recruiting to completed according to the results published in the Annals of Oncology .
01 Oct 2016 Results published in the Annals of Oncology (2016).
16 Feb 2016 Planned End Date changed from 1 Jan 2016 to 1 Aug 2016 as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com